UroGen Pharma (URGN) Earnings Date, Estimates & Call Transcripts $13.23 -0.50 (-3.64%) (As of 09/6/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 12EstimatedActual EPS (Aug. 13) -$0.91 Missed By -$0.09 Consensus EPS (Aug. 13) -$0.82 Get UroGen Pharma Earnings AlertsEnter your email address below to receive the latest news and earnings results for URGN and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueURGN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.URGN Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] UroGen Pharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.94)($0.94)($0.94)Q2 20241($0.77)($0.77)($0.77)Q3 20241($0.80)($0.80)($0.80)Q4 20241($0.77)($0.77)($0.77)FY 20244($3.28)($3.28)($3.28)Q1 20251($0.87)($0.87)($0.87)Q2 20251($0.87)($0.87)($0.87)Q3 20251($0.82)($0.82)($0.82)Q4 20251($0.77)($0.77)($0.77)FY 20254($3.33)($3.33)($3.33)URGN Earnings Date and InformationUroGen Pharma last announced its quarterly earnings results on August 13th, 2024. The reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.09. The company earned $21.85 million during the quarter, compared to analyst estimates of $23.69 million. UroGen Pharma has generated ($3.40) earnings per share over the last year (($3.40) diluted earnings per share). Earnings for UroGen Pharma are expected to grow in the coming year, from ($3.49) to ($2.85) per share. UroGen Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off prior year's report dates.Read More UroGen Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/12/2024(Estimated)------- 8/13/2024Q2 2024($0.82)($0.91)($0.09)($0.91)$23.69 million$21.85 million5/13/2024Q1 2024($0.93)($0.97)($0.04)($0.97)$20.73 million$18.78 million 3/14/2024Q4 2023($0.67)($0.72)($0.05)($0.72)$22.30 million$23.53 million 11/14/2023Q3 2023($0.89)($0.68)+$0.21($0.68)$19.80 million$20.85 million 8/10/2023Q2 2023($1.13)($1.03)+$0.10($1.03)$19.90 million$21.14 million 5/11/2023Q1 2023($1.39)($1.30)+$0.09($1.30)$16.55 million$17.19 million Get the Latest News and Ratings for URGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. 3/16/2023Q4 2022($1.12)($1.22)($0.10)($1.22)$18.25 million$18.09 million 11/10/2022Q3 2022($1.22)($1.13)+$0.09($1.13)$20.30 million$16.10 million 8/11/2022Q2 2022($1.33)($1.18)+$0.15($1.18)$16.95 million$16.60 million 5/10/2022Q1 2022($1.36)($1.25)+$0.11($1.25)$15.62 million$13.56 million 3/21/2022Q4 2021($1.18)($1.27)($0.09)($1.27)$16.15 million$16.17 million 11/15/2021Q3 2021($1.26)($1.35)($0.09)($1.35)$15.90 million$11.35 million 8/4/2021Q2 2021($1.10)($1.17)($0.07)($1.17)$13.00 million$13.03 million 5/13/2021Q1 2021($1.26)($1.17)+$0.09($1.17)$8.41 million$7.49 million 3/17/2021Q4 2020($1.37)($1.38)($0.01)($1.38)$7.21 million$7.97 million 11/9/2020Q3 2020($1.47)($1.31)+$0.16($1.31)$3.21 million$3.46 million 8/10/2020Q2 2020($1.59)($1.44)+$0.15($1.44)$0.50 million$0.37 million 5/7/2020Q1 2020($1.62)($1.79)($0.17)($1.79)-- 3/2/2020Q4 2019($1.70)($1.86)($0.16)($1.86)-- 11/12/2019Q3($1.26)($1.06)+$0.20($1.06)-- UroGen Pharma Earnings - Frequently Asked Questions When is UroGen Pharma's earnings date? UroGen Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off last year's report dates. Learn more on URGN's earnings history. Did UroGen Pharma beat their earnings estimates last quarter? In the previous quarter, UroGen Pharma (NASDAQ:URGN) missed the analysts' consensus estimate of ($0.82) by $0.09 with a reported earnings per share (EPS) of ($0.91). Learn more on analysts' earnings estimate vs. URGN's actual earnings. How much revenue does UroGen Pharma generate each year? UroGen Pharma (NASDAQ:URGN) has a recorded annual revenue of $82.71 million. How much profit does UroGen Pharma generate each year? UroGen Pharma (NASDAQ:URGN) has a recorded net income of -$102.24 million. URGN has generated -$3.40 earnings per share over the last four quarters. What is UroGen Pharma's EPS forecast for next year? UroGen Pharma's earnings are expected to grow from ($3.49) per share to ($2.85) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Akebia Therapeutics Earnings Puma Biotechnology Earnings RAPT Therapeutics Earnings Marinus Pharmaceuticals Earnings Molecular Templates Earnings Wave Life Sciences Earnings ANI Pharmaceuticals Earnings Sana Biotechnology Earnings Collegium Pharmaceutical Earnings Day One Biopharmaceuticals Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Is Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 EarningsNVIDIA: Analysts Bullish Ahead of Earnings - Is It a Buy Now? This page (NASDAQ:URGN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
